KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy

Clinical Cancer Research

Volumn 17, Issue 5, 2011, Pages 1111-1121

  Mortezavi, Ashkan ^a   Hermanns, Thomas ^a   Seifert, Hans Helge ^a   Baumgartner, Martin K ^a   Provenzano, Maurizio ^a   Sulser, Tullio ^a   Burger, Maximilian ^b   Montani, Matteo ^c   Ikenberg, Kristian ^a   Hofstadter, Ferdinand ^b   Hartmann, Arndt ^d   Jaggi, Rolf ^c   Moch, Holger ^a   Kristiansen, Glen ^a   Wild, Peter J ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

KARYOPHERIN; KARYOPHERIN ALPHA2; NIBRIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROSTATE SPECIFIC ANTIGEN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RECURRENCE; CANCER STAGING; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; UPREGULATION;

ALPHA KARYOPHERINS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE PROTEINS; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 79952254227     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0081     Document Type: Article

References (28)

1. Weissbach L, Altwein J. Active surveillance or active treatment in localized prostate cancer?Dtsch Arztebl Int 2009;106:371-6.
2. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004;101:811-6. (Pubitemid 38121040)
3. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006;24:268-73. (Pubitemid 46622055)
4. Foster CS, Falconer A, Dodson AR, Norman AR, Dennis N, Fletcher A, et al. Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 2004;23:5871-9. (Pubitemid 39093531)
5. Fleischmann A, Schlomm T, Huland H, Köllermann J, Simon P, Mirlacher M, et al. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients. Clin Cancer Res 2008;14:7838-42.
6. Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P, et al. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996;178:437-41. (Pubitemid 26145136)
7. Rabien A, Burkhardt M, Jung M, Fritzsche F, Ringsdorf M, Schicktanz H, et al. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy. Eur Urol 2007;51:1259-66. (Pubitemid 46436286)
8. Fritzsche FR, Jung M, Tolle A, Wild P, Hartmann A, Wassermann K, et al. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol 2008;54:1097-106.
9. Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008;98:604-10. (Pubitemid 351214528)
10. Kristiansen G, Pilarsky C, Wissmann C, Kaiser S, Bruemmendorf T, Roepcke S, et al. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 2005;205:359-76. (Pubitemid 40253926)
11. Dahl E, Kristiansen G, Gottlob K, Klaman I, Ebner E, Hinzmann B, et al. Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer. Clin Cancer Res 2006;12:3950-60. (Pubitemid 44078080)
12. Gluz O, Wild P, Meiler R, Diallo-Danebrock R, Ting E, Mohrmann S, et al. Nuclear karyopherin alpha2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity. Int J Cancer 2008;123:1433-8.
13. Dankof A, Fritzsche FR, Dahl E, Pahl S, Wild P, Dietel M, et al. KPNA2 protein expression in invasive breast carcinoma and matched peritumoral ductal carcinoma in situ. Virchows Arch 2007;451:877-81. (Pubitemid 350060752)
14. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7. (Pubitemid 28331029)
15. Epstein JI, Allsbrook WC Jr., Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228-42.
16. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63. (Pubitemid 14203433)
17. Nigg EA, Krek W, Peter M. Vertebrate cdc2 kinase: its regulation by phosphorylation and its mitotic targets. Cold Spring Harb Symp Quant Biol 1991;56:539-47.
18. Leung SW, Harreman MT, Hodel MR, Hodel AE, Corbett AH. Dissection of the karyopherin alpha nuclear localization signal (NLS)-binding groove: functional requirements for NLS binding. J Biol Chem 2003;278:41947-53. (Pubitemid 37310457)
19. Chook YM, Blobel G. Karyopherins and nuclear import. Curr Opin Struct Biol 2001;11:703-15. (Pubitemid 34076632)
20. Tseng SF, Chang CY, Wu KJ, Teng SC. Importin KPNA2 is required for proper nuclear localization and multiple functions of NBS1. J Biol Chem 2005;280:39594-600.
21. Antoccia A, Kobayashi J, Tauchi H, Matsuura S, Komatsu K. Nijmegen breakage syndrome and functions of the responsible protein, NBS1. Genome Dyn 2006;1:191-205.
22. Teng SC, Wu KJ, Tseng SF, Wong CW, Kao L. Importin KPNA2, NBS1, DNA repair and tumorigenesis. J Mol Histol 2006;37:293-9.
23. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004;351:1488-90. (Pubitemid 39315314)
24. Cutress ML, Whitaker HC, Mills IG, Stewart M, Neal DE. Structural basis for the nuclear import of the human androgen receptor. J Cell Sci 2008;121:957-68. (Pubitemid 351639415)
25. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009;41:619-24.
26. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 2006;98:472-82.
27. van der Watt PJ, Maske CP, Hendricks DT, Parker MI, Denny L, Govender D, et al. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer 2009;124:1829-40.
28. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:845-56. (Pubitemid 41746029)